New pill for EGFR Exon 20 lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of lung cancer called non-squamous non-small cell lung cancer that has spread and cannot be removed by surgery.
- Your tumor must have a specific EGFR genetic change called exon 20 insertion.
- You cannot have had any previous treatment for advanced or spreading lung cancer.
- You must be in good physical condition (able to care for yourself and do light activities).
- Your life expectancy should be at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
This trial tests a new drug called BEBT-109 for people with a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It's for those who haven't had prior treatment for advanced or metastatic lung cancer, and it aims to see if the drug can help shrink or control the cancer.
This trial tests an experimental pill called BEBT-109 for people with a specific type of lung cancer (EGFR exon 20 insertion mutation) that has gotten worse after chemotherapy. The study aims to see if this targeted therapy can shrink tumors or slow cancer growth.
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
This trial tests a new targeted therapy (vebreltinib plus PLB1004) against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific change (EGFR mutation) and MET protein, and has stopped responding to earlier EGFR treatment.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.